Format

Send to

Choose Destination
Histochem Cell Biol. 2008 May;129(5):563-78. doi: 10.1007/s00418-008-0401-3. Epub 2008 Feb 21.

Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer.

Author information

1
Department of Cellular and Molecular Medicine, the Panum Institute, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark. kirroep@sund.ku.dk

Abstract

ErbB receptors (EGFR (ErbB1), ErbB2, ErbB3, and ErbB4) are important regulators of normal growth and differentiation, and they are involved in the pathogenesis of cancer. Following ligand binding and receptor activation, EGFR is endocytosed and transported to lysosomes where the receptor is degraded. This downregulation of EGFR is a complex and tightly regulated process. The functions of ErbB2, ErbB3, and ErbB4 are also regulated by endocytosis to some extent, although the current knowledge of these processes is sparse. Impaired endocytic downregulation of signaling receptors is frequently associated with cancer, since it can lead to increased and uncontrolled receptor signaling. In this review we describe the current knowledge of ErbB receptor endocytic downregulation. In addition, we outline how ErbB receptors can escape endocytic downregulation in cancer, and we discuss how targeted anti-cancer therapy may induce endocytic downregulation of ErbB receptors.

PMID:
18288481
PMCID:
PMC2323030
DOI:
10.1007/s00418-008-0401-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center